Trans-palmitoleic acid, metabolic risk factors, and new-onset diabetes in U.S. adults: a cohort study
- PMID: 21173413
- PMCID: PMC3056495
- DOI: 10.7326/0003-4819-153-12-201012210-00005
Trans-palmitoleic acid, metabolic risk factors, and new-onset diabetes in U.S. adults: a cohort study
Abstract
Background: Palmitoleic acid (cis-16:1n-7), which is produced by endogenous fat synthesis, has been linked to both beneficial and deleterious metabolic effects, potentially confounded by diverse determinants and tissue sources of endogenous production. Trans-palmitoleate (trans-16:1n-7) represents a distinctly exogenous source of 16:1n-7, unconfounded by endogenous synthesis or its determinants, that may be uniquely informative.
Objective: To investigate whether circulating trans-palmitoleate is independently related to lower metabolic risk and incident type 2 diabetes.
Design: Prospective cohort study from 1992 to 2006.
Setting: Four U.S. communities.
Patients: 3736 adults in the Cardiovascular Health Study.
Measurements: Anthropometric characteristics and levels of plasma phospholipid fatty acids, blood lipids, inflammatory markers, and glucose-insulin measured at baseline in 1992 and dietary habits measured 3 years earlier. Multivariate-adjusted models were used to investigate how demographic, clinical, and lifestyle factors independently related to plasma phospholipid trans-palmitoleate; how trans-palmitoleate related to major metabolic risk factors; and how trans-palmitoleate related to new-onset diabetes (304 incident cases). Findings were validated for metabolic risk factors in an independent cohort of 327 women.
Results: In multivariate analyses, whole-fat dairy consumption was most strongly associated with higher trans-palmitoleate levels. Higher trans-palmitoleate levels were associated with slightly lower adiposity and, independently, with higher high-density lipoprotein cholesterol levels (1.9% across quintiles; P = 0.040), lower triglyceride levels (-19.0%; P < 0.001), a lower total cholesterol-HDL cholesterol ratio (-4.7%; P < 0.001), lower C-reactive protein levels (-13.8%; P = 0.05), and lower insulin resistance (-16.7%, P < 0.001). Trans-palmitoleate was also associated with a substantially lower incidence of diabetes, with multivariate hazard ratios of 0.41 (95% CI, 0.27 to 0.64) and 0.38 (CI, 0.24 to 0.62) in quintiles 4 and 5 versus quintile 1 (P for trend < 0.001). Findings were independent of estimated dairy consumption or other fatty acid dairy biomarkers. Protective associations with metabolic risk factors were confirmed in the validation cohort.
Limitation: Results could be affected by measurement error or residual confounding.
Conclusion: Circulating trans-palmitoleate is associated with lower insulin resistance, presence of atherogenic dyslipidemia, and incident diabetes. Our findings may explain previously observed metabolic benefits of dairy consumption and support the need for detailed further experimental and clinical investigation.
Primary funding source: National Heart, Lung, and Blood Institute and National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health.
Conflict of interest statement
Comment in
-
Summaries for patients. Dietary trans-palmitoleic acid and diabetes.Ann Intern Med. 2010 Dec 21;153(12):I-56. doi: 10.7326/0003-4819-153-12-201012210-00002. Ann Intern Med. 2010. PMID: 21173398 No abstract available.
Similar articles
-
trans-Palmitoleic acid, other dairy fat biomarkers, and incident diabetes: the Multi-Ethnic Study of Atherosclerosis (MESA).Am J Clin Nutr. 2013 Apr;97(4):854-61. doi: 10.3945/ajcn.112.045468. Epub 2013 Feb 13. Am J Clin Nutr. 2013. PMID: 23407305 Free PMC article. Clinical Trial.
-
Circulating palmitoleic acid and risk of metabolic abnormalities and new-onset diabetes.Am J Clin Nutr. 2010 Dec;92(6):1350-8. doi: 10.3945/ajcn.110.003970. Epub 2010 Oct 13. Am J Clin Nutr. 2010. PMID: 20943795 Free PMC article.
-
Summaries for patients. Dietary trans-palmitoleic acid and diabetes.Ann Intern Med. 2010 Dec 21;153(12):I-56. doi: 10.7326/0003-4819-153-12-201012210-00002. Ann Intern Med. 2010. PMID: 21173398 No abstract available.
-
The Role of the Novel Lipokine Palmitoleic Acid in Health and Disease.Adv Nutr. 2017 Jan 17;8(1):173S-181S. doi: 10.3945/an.115.011130. Print 2017 Jan. Adv Nutr. 2017. PMID: 28096141 Free PMC article. Review.
-
Implications of Palmitoleic Acid (Palmitoleate) On Glucose Homeostasis, Insulin Resistance and Diabetes.Curr Drug Targets. 2017;18(6):619-628. doi: 10.2174/1389450117666151209120345. Curr Drug Targets. 2017. PMID: 26648072 Review.
Cited by 108 articles
-
Effect of dairy consumption and its fat content on glycemic control and cardiovascular disease risk factors in patients with type 2 diabetes: a randomized controlled study.Am J Clin Nutr. 2020 Aug 1;112(2):293-302. doi: 10.1093/ajcn/nqaa138. Am J Clin Nutr. 2020. PMID: 32520346
-
Dairy Consumption and Cardiometabolic Risk Factors in Patients with Type 2 Diabetes and Overweight or Obesity during Intensive Multidisciplinary Weight Management: A Prospective Observational Study.Nutrients. 2020 Jun 2;12(6):1643. doi: 10.3390/nu12061643. Nutrients. 2020. PMID: 32498266 Free PMC article.
-
Plasma Trans Fatty Acid Levels, Cardiovascular Risk Factors and Lifestyle: Results from the Akershus Cardiac Examination 1950 Study.Nutrients. 2020 May 14;12(5):1419. doi: 10.3390/nu12051419. Nutrients. 2020. PMID: 32423040 Free PMC article.
-
Cow's Milk Fat Obesity pRevention Trial (CoMFORT): a primary care embedded randomised controlled trial protocol to determine the effect of cow's milk fat on child adiposity.BMJ Open. 2020 May 7;10(5):e035241. doi: 10.1136/bmjopen-2019-035241. BMJ Open. 2020. PMID: 32385063 Free PMC article.
-
Current intakes of trans-palmitoleic (trans-C16:1 n-7) and trans-vaccenic (trans-C18:1 n-7) acids in France are exclusively ensured by ruminant milk and ruminant meat: A market basket investigation.Food Chem X. 2020 Feb 12;5:100081. doi: 10.1016/j.fochx.2020.100081. eCollection 2020 Mar 30. Food Chem X. 2020. PMID: 32149276 Free PMC article.
Publication types
MeSH terms
Substances
Grant support
- DK71507-04/DK/NIDDK NIH HHS/United States
- R90 DK071507/DK/NIDDK NIH HHS/United States
- N01-HC-85085/HC/NHLBI NIH HHS/United States
- R01 HL085710/HL/NHLBI NIH HHS/United States
- U01 HL080295/HL/NHLBI NIH HHS/United States
- N01-HC-85081/HC/NHLBI NIH HHS/United States
- U01-HL080295/HL/NHLBI NIH HHS/United States
- R01 DK064360/DK/NIDDK NIH HHS/United States
- R01-HL085710/HL/NHLBI NIH HHS/United States
- N01 HC015103/HC/NHLBI NIH HHS/United States
- N01HC55222/HL/NHLBI NIH HHS/United States
- N01-HC-85086/HC/NHLBI NIH HHS/United States
- N01-HC-85082/HC/NHLBI NIH HHS/United States
- R01 HL085710-04/HL/NHLBI NIH HHS/United States
- DK064360/DK/NIDDK NIH HHS/United States
- N01-HC-55222/HC/NHLBI NIH HHS/United States
- N01-HC-85083/HC/NHLBI NIH HHS/United States
- N01-HC-75150/HC/NHLBI NIH HHS/United States
- N01-HC-85080/HC/NHLBI NIH HHS/United States
- R56 DK064360/DK/NIDDK NIH HHS/United States
- N01HC75150/HL/NHLBI NIH HHS/United States
- N01-HC-85079/HC/NHLBI NIH HHS/United States
- N01HC85079/HL/NHLBI NIH HHS/United States
- N01 HC045133/HC/NHLBI NIH HHS/United States
- N01 HC035129/HC/NHLBI NIH HHS/United States
- N01-HC-85084/HC/NHLBI NIH HHS/United States
LinkOut - more resources
-
Full Text Sources
-
Other Literature Sources
-
Medical
-
Miscellaneous